Selective androgen receptor modulators: the future of androgen therapy?
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while eschewing the pitfalls of traditional androgen therapy. SARMs have few side effects and excellent oral and transdermal bioavailability and may, therefore, represent viable alternatives to current androgen therapies. SARMs have been studied as possible therapies for many conditions, including osteoporosis, Alzheimer's disease, breast cancer, stress urinary incontinence (SUI), prostate cancer (PCa), benign prostatic hyperplasia (BPH), male contraception, hypogonadism, Duchenne muscular dystrophy (DMD), and sarcopenia/muscle wasting/cancer cachexia. While there are no indications for SARMs currently approved by the Food and Drug Administration (FDA), many potential applications are still being explored, and results are promising. In this review, we examine the literature assessing the use of SARMS for a number of indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0034-6 · Cited by 403
Dobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Development of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251 · cited 3×
“However, because they are not metabolized to dihydrotestosterone (DHT) by 5 -reductase, the risk of androgenic effects is reduced (27,38).”
BackgroundMethodCrawford, J., Prado, C. M. M., Johnston, M. A., Gralla, R. J., Taylor, R. P., Hancock, M. L., & Dalton, J. T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0522-0 · Cited by 178 · cited 2×
“The AR is essential both for its role in male sexual development and maintenance but also has the potential to alter bone density, strength, muscle mass, hematopoiesis, coagulation, metabolism, and cognition (26,27).”
BackgroundSelective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.09.006 · Cited by 174 · cited 10×
“FL442 acted as an AR antagonist in the PCa cell models with efficacy comparable to that of enzalutamide (4,58).”
BackgroundResultInfluentialSelf-citationSjøblom, B., Grønberg, B. H., Wentzel-Larsen, T., Baracos, V. E., Hjermstad, M. J., Aass, N., Bremnes, R. M., Fløtten, Ø., Bye, A., & Jordhøy, M. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.010 · Cited by 143 · cited 1×
“Studies have demonstrated that survival of cancer patients correlates directly with muscle mass (72-74) and that sarcopenia is associated with increased mortality (75).”
BackgroundDalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0000000000000015 · Cited by 91 · cited 13×
“This allows for targeted therapeutic benefits with the absence of adverse off-target effects, which is currently a significant limitation of TTh. SARMs are well tolerated, and their oral bioavailability provides a substantial advantage over other methods of androgen therapy.”
BackgroundInfluentialNovel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31 · cited 1×
“In addition to their potential use for the treatment of hypogonadism (7,8), SARMs are being explored as a potential therapy for osteopenia/osteoporosis (9-14), A lzhe imer ’s d i sease (15) , pros ta te cancer (PCa) (16,17), benign prostatic hyperplasia (BPH) (18), male contraception (19), breast cancer (20), stress-i…”
BackgroundWatanabe, K., Hirata, M., Tominari, T., Matsumoto, C., Endo, Y., Murphy, G., Nagase, H., Inada, M., & Miyaura, C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.027 · Cited by 28
Piper, T., Dib, J., Putz, M., Fusshöller, G., Pop, V., Lagojda, A., Kuehne, D., Geyer, H., Schänzer, W., & Thevis, M. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2527 · Cited by 23 · cited 1×
“As such, efforts are currently focused on continuing to isolate metabolites from novel SARMs for drug testing (89,90), and multiple SARMs have already been added by the World Anti-Doping Agency (WADA) to the Prohibited List (91).”
Background
Cited by
Current and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Our evolving understanding of how 27-hydroxycholesterol influences cancer
Ma, L., Cho, W., & Nelson, E. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114621 · Cited by 53
RISING STARS: androgens and immune cell function
Ainslie, R. J., Simitsidellis, I., Kirkwood, P. M., & Gibson, D. A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0398 · Cited by 48
Metadata
- Authors
- Christiansen, A. R., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W.
- Venue
- Translational Andrology and Urology
- Publisher
- AME Publishing Company
- Published
- 2020-03
- Volume
- 9
- Issue
- S2
- Pages
- S135-S148
- ISSN
- 2223-4683 (ISSN-L)
- 2223-4691
- OpenAlex
- W2994604855
- Cited by
- 128
- References
- 13
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.